



ASBAI

Associação Brasileira de
Alergia e Imunologia




**UNIFESP/EPM
PEDIATRIA**

II ENCONTRO ASBAI – BRAGID

Mariana Gouveia Pereira, MD

FEDERAL UNIVERSITY OF SÃO PAULO, BRAZIL

- FMS, male, born full-term
- Third child of non-consanguineous parents
- Symptoms started at 3 years old



Laboratory Findings at Diagnosis

Ferritin	6578 ng/ml
Triglycerides	368 mg/dl
Fibrinogen	200 mg/dl
Hemoglobin	8,9 g/dl
Leukocyte	5000 / m3
Platelets	53.000 / m3
DHL	1927 mg/dl
TGO/ TGP	1682 / 854 U/L

Abdomen CT = Hepatomegaly.

Myelogram – hypocellular bone marrow, hemophagocytosis

Hemophagocytic Syndrome

- Immunologic, Rheumatologic, Oncologic, Infectious diseases was excluded
- Pulsotherapy was done for 3 days (Methylprednisolone), 1 month after the first symptoms (2015/jun)
- Genetic Panel: No pathogenic variants

ADA, IL2RG, IL7R, RAG1, RAG2, JAK3, CD3D, CD3E, CD3G, CD247, CD8A, NFKBIA, CIITA, DCLRE1C, FOXP1, LIG4,
NHEJ1, PTPRC, PNP, RFX5, RFXANK, RFXAP, TAP1, TAP2, TAPBP, BTK, CD70A, CD70B, BLNK, CD19, IGLL1, LRRC8A,
STAT3, MS4A1, AICDA, CD40, CD40LG, UNC SH2D1A, PRF1, STX11, STXBP2, UNC13D, XIAP, FAS, FASLG, CASP8,
CASP10, NRAS, FOXP3, IFNGR1, IFNGR2, IL12RB1, STAT1, ELANE, GFI1, HAX1, MPO, G6PC3, RAC2, CYBA, CYBB, NCF1,
NCF2, NCF4, MYD88, SERPING1, WAS, WIPF1, LYST, RAB27A, CATA2, ORAI1, PIK3CD, MAGT1, STAT5B, EDA.

- He maintained pruriginous exanthema




3 days IVIG was done (2015/jun) with remission
(Ferritin = 43)

- 2015/ sept: Reactivation

Fever + Exanthema +
Increase Ferritin (4x basal) and trigliceryde



HLH 2004 Protocol was started

Figure 1: Flow-sheet for Children with Hemophagocytic Lymphohistiocytosis (HLH) in HLH-2004

* If there is a treatable infection it should be treated but be aware that this may not be sufficient and the patient may need HLH-treatment in addition. All severe forms should start HLH-treatment. If HLH is persistent or recurring consider that the patient may have an undiagnosed inherited disease. HLH may also develop secondary to a number of other diseases as malignancies, rheumatic diseases and metabolic disorders, requiring a different treatment.

Start therapy if the patient has a genetically verified disease, a familial form of HLH, or if the disease is severe, persistent, or recurrent.

HSCT was indicated

Avaliation pré- HSCT was done → CNS disease was diagnosed

MTX intratecal was started

HSCT was done in march,03 2016

